Dermata Therapeutics Warrant Stock Price To Earnings To Growth
DRMAW Stock | USD 0.02 0 11.11% |
Dermata Therapeutics Warrant fundamentals help investors to digest information that contributes to Dermata Therapeutics' financial success or failures. It also enables traders to predict the movement of Dermata Stock. The fundamental analysis module provides a way to measure Dermata Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dermata Therapeutics stock.
Dermata | Price To Earnings To Growth |
Dermata Therapeutics Warrant Company Price To Earnings To Growth Analysis
Dermata Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Dermata Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Dermata Therapeutics is extremely important. It helps to project a fair market value of Dermata Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Dermata Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dermata Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dermata Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition |
Dermata Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Dermata Therapeutics Warrant has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Dermata Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Dermata Therapeutics from analyzing Dermata Therapeutics' financial statements. These drivers represent accounts that assess Dermata Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Dermata Therapeutics' important valuation drivers and their relationship over time.
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Enterprise Value | 651.4M | 206.6M | 61.6M | (1.1M) | (1.3M) | (1.2M) |
Dermata Fundamentals
Return On Equity | -3.1 | ||||
Return On Asset | -1.36 | ||||
Number Of Shares Shorted | 28.04 K | ||||
EBITDA | (12.51 B) | ||||
Net Income | (12.29 B) | ||||
Total Debt | 1.97 B | ||||
Book Value Per Share | 0.62 X | ||||
Cash Flow From Operations | (11.16 B) | ||||
Earnings Per Share | (2.16) X | ||||
Beta | 0.65 | ||||
Total Asset | 3.53 B | ||||
Retained Earnings | (65.68 B) | ||||
Working Capital | 1.56 M | ||||
Net Asset | 3.53 B |
About Dermata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.ZLAB | Zai Lab | |
ASLE | AerSale Corp | |
ATS | AT S Austria |
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.